ArticleWorld journal of surgical oncology2026
LY86-AS1 predicts poor prognosis and inhibits progression in non-small cell lung cancer by targeting the miR-132-3p/RB1CC1 axis.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer cases. Despite significant advances in surgery, radiotherapy, chemotherapy, and targeted and immunotherapy, the overall five-year survival of NSCLC patients is still dismally low. The objective of this investigation was to evaluate the potential of LY86-AS1 as a prognostic biomarker in NSCLC and to elucidate its associated molecular regulatory network.
methodsExpression levels of LY86-AS1, miR-132-3p, and RB1CC1 were detected in NSCLC tissues and cell lines using RT-qPCR. The correlation of LY86-AS1 expression with clinical pathological characteristics was evaluated using the Kaplan-Meier curve and multivariate Cox regression analysis. CCK-8 and Transwell assays were then performed to test the effects of LY86-AS1, miR-132-3p, and RB1CC1 on the proliferation, migration, and invasion of NCI-H1299 and A549 cells.
resultsLY86-AS1 was significantly underexpressed in NSCLC. Low levels of LY86-AS1 were strongly associated with a poor prognosis and were independent prognostic factors. Overexpression of LY86-AS1 significantly inhibited the proliferation, migration, and invasion of NSCLC cells. Mechanistically, overexpression of miR-132-3p reversed the inhibitory effect of LY86-AS1 on NSCLC cells, while the overexpression of RB1CC1 abolished the oncogenic effect of miR-132-3p.
conclusionsLY86-AS1 upregulates RB1CC1 expression by sponging miR-132-3p, thereby inhibiting the malignant progression of NSCLC and is a potential prognostic biomarker and therapeutic target for NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.